中超控股(002471.SZ):擬出資1億元投設醫美健康投資管理公司
格隆匯6月15日丨中超控股(002471.SZ)公佈,公司擬以自有資金人民幣1億元投資設立“江蘇中超醫美健康投資管理有限公司”,佔註冊資金的100%。
公司表示,電線電纜是傳統的重資產行業,資金依賴度較高且利潤空間有限。該次投資是進一步落實公司戰略佈局:在做好現有傳統產業主業的同時,選擇成長潛力大、資產負擔輕的醫美產業作為公司未來第二主業,有利於公司在維持現有業務的基礎上開闢新的業務領域,提升公司的綜合競爭力,保持公司健康、可持續發展。
擬投資公司設立後,可與電線電纜產業形成輕重資產優勢互補,在有效降低經營風險的同時可作為新的盈利增長點,促進公司多元化發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.